IHE iShares U.S. Pharmaceuticals ETF

iShares U.S. Pharmaceuticals ETF (IHE) currently reports 57 stock positions (subject to change), placing it in the moderately spread range by holdings breadth. The top line-up is JNJ (23.04%), LLY (21.07%), MRK (4.74%), with JNJ as the largest single weight at 23.04%. Together, the top three holdings account for 48.85%, which suggests investors should pay close attention to the largest holdings, as they carry outsized influence on aggregate returns. The overall construction balances concentrated exposure at the top with broader diversification through the rest of the book.

Through the lens of capital efficiency, ROIC is 14.27%, WACC is 6.47%, and the economic spread is 7.79%. On balance, ROIC edges above WACC, suggesting the businesses are value-creative in aggregate, if not dramatically so. Supporting metrics show ROE at 26.90% and ROA at 6.47%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio that is value-creative but with less room for execution slippage.

From a market pricing perspective, trailing P/E of 21.84, forward P/E of 14.39, PEG of 1.86. A modest gap between trailing and forward multiples implies the market is pricing incremental earnings improvement rather than a step-change in profitability. On a growth-adjusted basis, valuation appears reasonable relative to expected growth. The portfolio's weighted current ratio of 3.57 signals strong near-term financial resilience. The overall valuation picture is one where the market is paying for a specific earnings and growth outcome — and where any deviation from that path would likely pressure multiples.

The margin profile breaks down as follows: gross margin sits at 73.94%, operating margin at 19.30%, and free cash flow margin at 18.93%. The portfolio's gross margin reflects businesses that retain a large share of revenue before overhead — a sign of genuine competitive insulation. Operating margins are solid, reflecting adequate cost control relative to the revenue base. The portfolio's FCF margin is healthy, indicating solid cash conversion after capital expenditure needs. The mixed margin profile here calls for selectivity — the portfolio's quality of earnings is not uniform across the holding set.

The growth and outlook picture reads as follows: TTM revenue growth of 22.06% pointing to healthy demand conditions for the businesses represented in the fund. In parallel, analysts project moderate appreciation over the next 12 months based on current consensus targets. The gap between trailing fundamentals and forward expectations matters most at inflection points — and the current environment is not without those. For long-term holders, the central question is whether today's execution quality is a leading indicator of what's already priced into analyst targets. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Reviewed in aggregate, this is a high-quality profile with few clear structural weaknesses — a combination that historically tends to support above-average long-term outcomes.

This assessment reflects quantitative metrics only and does not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.